PharmaTech

JUNE 30, 2025

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com Hikma Pharmaceuticals USA announced on June 28, 2025 that it is investing $1 billion by 2030 to expand its generic-drug R&D and manufacturing capabilities in its Ohio and New Jersey, United States, facilities.

Dosage 59

Dosage Drug Development Generic Medicine Vaccines 59

PharmaTech

JUNE 26, 2025

million) in non-dilutive funding through i-Nov, an innovation competition and flagship French government program that is part of the France 2030 initiative, operated by Bpifrance (1). Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs Paul L. Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs Paul L.

Dosage 59

Dosage Drug Development Vaccines Labelling 59

PharmaTech

JULY 7, 2025

billion) by 2030 (1). One-quarter of patients who suffer a hip fracture die within one year, Theramex said, with hip fractures costing NHS £2 billion (US$2.7 billion) per year and osteoporotic fractures presently accounting for more than £4.6 billion (US$6.3 billion) of direct costs to NHS, forecast to increase to £6 billion (US$8.2

Dosage 49

Dosage Drug Development Chemotherapy Vaccines 49

Pharmaceutical Technology

JULY 21, 2025

Both companies plan to further innovate partnerships within the medical industry’s digital landscape, aiming to improve patient outcomes and also contribute towards achieving national Healthy China 2030 objectives.

Diabetes 52

Diabetes Packaging Communication Hospitals 52

Pharmaceutical Technology

JULY 14, 2025

The global RSV market is set to reach $6.3bn in value by 2030, according to analysis by GlobalData. Around 64 million people of all ages globally every year are impacted by RSV, a common respiratory virus that causes seasonal infections such as the flu. It is also a leading cause of pneumonia and death in infants and older adults.

Labelling 52

Labelling Vaccines Insurance Coverage and Processing Packaging 52

Pharmaceutical Technology

JUNE 26, 2025

The group had set a fundraising target of $11.9bn for its 2026-2030 budget. Robert Barrie June 26, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Gavi conducted a fundraiser at its annual Global Summit held in Brussels on 25 June. The organisation raised more than $9bn, less than it had targeted.

Vaccines 59

Vaccines Packaging Communication Hospitals 59

STAT

DECEMBER 5, 2023

Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030. Plenty of people in pharma and at the banks that invest in it seem to think so. Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical. 

Drug Pricing 299

Drug Pricing Drug Development 299

STAT

FEBRUARY 29, 2024

It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.)

Drug Development 359

Drug Development 359

European Pharmaceutical Review

JUNE 28, 2023

million by 2030, growing at a compound annual growth rate (CAGR) of 5.57 percent from 2023 to 2030. Growth of the pharmaceutical and biotechnology industries, plus the need for accurate and precise analytical tools in drug development and quality control are influencing factors. percent between 2023 and 2030.

Drug Development 98

Drug Development Compounding 98

European Pharmaceutical Review

SEPTEMBER 12, 2023

Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development , within the next 24-months. Attending CPHI Barcelona 2023?

Drug Development 105

Drug Development Pharmaceutical Companies Pharmaceutical Companies 105

European Pharmaceutical Review

AUGUST 17, 2022

According to a recent report , the global formulation development outsourcing market size should grow to $61.4 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide.

Compounding 96

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Development 96

Pharma Mirror

NOVEMBER 23, 2021

AI is an emerging technology that is being applied in numerous facets of the pharma sector, ranging from drug development to diagnosis and even patient care. The post AI in Pharma and Biotech Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2030 appeared first on Pharma Mirror Magazine.

Drug Development 52

Drug Development 52

European Pharmaceutical Review

APRIL 3, 2024

Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. percent between 2022-2030. This is contributing to a more streamlined and efficient approach to drug development, according to the report. percent between 2022-2030.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Biosimilars Compounding 52

Express Pharma

JULY 21, 2024

Indian Pharmaceutical sector trying to reach the USD 130 Billion target by 2030. 2) R&D Engine: The industry seeks increased incentives for research and development, such as tax deductions. This may fuel innovation, particularly for diseases prevalent in India.

Biosimilars 105

Biosimilars Pharmaceutical Companies Pharmaceutical Companies Drug Development 105

European Pharmaceutical Review

MAY 2, 2024

As a result, the market is expected to reach $719 billion by 2030, 1 Sigma Mostafa, PhD, Chief Scientific Officer at KBI Biopharma shared with EPR. In vitro organoid models are also becoming popular in oncology drug development. Bn by 2030. References Biologics Market Size to Worth Around US$ 719.84 cited 2024May].

Biosimilars 105

Biosimilars Drug Development 105

pharmaphorum

JUNE 8, 2021

All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. The entire APAC region already accounts for 30% of all global pharma spending, and within these markets national healthcare expenditure is expected to increase threefold to over $2 trillion by 2030.

Chemotherapy 106

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunity 106

European Pharmaceutical Review

SEPTEMBER 21, 2023

billion by 2030. In this Q&A, Karen Pinachyan, Head of Medical Affairs Europe at CSL Behring summarises key considerations for gene therapy drug development and the ideal approach for alleviating economic strain when advancing these modern treatments. How has the gene therapy landscape evolved over the last several years?

Drug Development 96

Drug Development Pharmaceutical Companies Pharmaceutical Companies Diabetes 96

European Pharmaceutical Review

JULY 24, 2023

QMS market to value nearly $4b by 2030 A strategy for improving drug product quality Uriel et al. International regulation: the importance of quality assurance in drug development The post Establishing quality assurance in personalised preparations appeared first on European Pharmaceutical Review. Uriel et al.

Compounding 93

Compounding Documentation Drug Development 93

Express Pharma

APRIL 17, 2025

What are the major advancements in drug development research? Drug development research has made remarkable progress globally, with India emerging as a key contributor. How can AI help accelerate drug development? What are the opportunities for India in the current landscape?

Drug Development 66

Drug Development Hospitals 66

Pharma Marketing Network

MARCH 25, 2022

By 2030, it is estimated there will be only 4 potential family caregivers per older adult and some are also caring for children of their own. The FDA has studied the importance of caregivers to drug development and regulatory decision-making. 2 In 2019, there were 7 potential family caregivers per older adult.

Labelling 98

Labelling Drug Development 98

pharmaphorum

MARCH 10, 2022

Biologics product development has increased steadily over the past decade, with the volume of business forecast to double by 2030. As such, companies are rethinking the existing landscape of drug development. The rise of biologics.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Packaging Immunity 98

pharmaphorum

JULY 28, 2021

Under the agreement, Calico is responsible for research and early development until 2025 and will take projects through phase 2a trials until 2030, with AbbVie having an option to take over projects once they reach later-stage development and lead commercialisation efforts.

Immunity 59

Immunity Immunization Drug Development 59

European Pharmaceutical Review

JANUARY 4, 2023

WuXi STA , a subsidiary of WuXi AppTec, has announced that its first continuous manufacturing ( CM ) line for oral solids is in operation at its drug product site in Wuxi city, China. billion by 2030. Oral solids are the most popular mode of drug delivery due to being highly cost-effective and offering simple manufacturing processes.

Dosage 52

Dosage Drug Development 52

Definitive Healthcare

FEBRUARY 23, 2024

Resource Type E-Books & How-To Guides Blog How-To Guide Healthcare Insight Medical claims 101: What you need to know How to sell effectively to healthcare facilities and executives using the right… Hospital payor mix by state Image Image Image ","nextArrow":" ","appendArrows":".coh-slider-nav-bottom","dots":false,"draggable":true,"swipe":true,"fade":false,"vertical":false,"speed":700,"cssEase":"ease","pauseOnHover":false,"pauseOnDotsHover":false,"autoplay":false,"rows":0},"sm":{"slidesToShow":2,

Drug Pricing 52

Drug Pricing Hospitals Drug Development 52

European Pharmaceutical Review

MARCH 24, 2023

In the European Union, NASH affects nearly 10 million people and is expected to increase by more than 40 percent by 2030. Before Ultragenyx, Dr Mansbach served as VP of medical affairs at Medivation, where he played a key role in the development and commercialisation of enzalutamide for advanced prostate cancer.

Drug Development 108

Drug Development 108

European Pharmaceutical Review

OCTOBER 24, 2024

billion in 2030, respectively.” Professor Morgan proposed that Alzheimer’s drug development needs to move “beyond the focus on amyloid clearance and targeting other aspects of the disease that may provide better, safer and affordable routes to effective therapy.” billion and $2.0

Drug Development 52

Drug Development 52

pharmaphorum

JANUARY 16, 2023

Analysts at GlobalData said last year that they expect LY03010 to launch in 2024 and bring in sales of around $64 million in 2030. ” The post Luye claims its first FDA approval, for bi-weekly schizophrenia drug appeared first on.

Drug Development 52

Drug Development 52

pharmaphorum

AUGUST 2, 2022

Merck is no stranger to ADC technology; over the past few years the company has steadily added ADC drug candidates to its pipeline, including through a $2.75 billion deal for VelosBio , a research agreement with Starpharma , and a previous drug development deal with Seagen , under its former name Seattle Genetics.

Compounding 98

Compounding Drug Development 98

Express Pharma

SEPTEMBER 17, 2024

The industry is poised for considerable growth in the near future and is expected to reach $130 billion by 2030 (currently valued at $50 billion) (1). With an aim to become more value-driven, India’s pharma industry is looking beyond generics, targeting innovations in drug development.

Communication 105

Communication Drug Development 105

European Pharmaceutical Review

DECEMBER 21, 2022

In the context of CO 2 neutrality, the years 2030 and 2050 are mentioned as crucial milestones. He is currently group leader of the Technology Development and Discovery Group at the Bioprocess Laboratory of the ETH. The lengthy validation of defossilised organic chemicals and plastics for the healthcare sector will take several years.

Compounding 97

Compounding Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies 97

PharmaShots

JUNE 14, 2023

Labcorp Diagnostics and Labcorp Development are the two business segments under which the company operates.

Hospitals 56

Hospitals Documentation Drug Development 56

Safe Biologics

JUNE 12, 2023

Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. Mr. Spiegel is a founding member of ASBM and Executive Director of the Global Colon Cancer Association.

Drug Pricing 100

Drug Pricing Drug Development Compounding 100

Safe Biologics

JUNE 12, 2023

Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. Mr. Spiegel is a founding member of ASBM and Executive Director of the Global Colon Cancer Association.

Drug Pricing 100

Drug Pricing Drug Development Compounding 100

STAT

DECEMBER 13, 2024

Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Meanwhile, the U.S.

Pharmaceutical Companies 248

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Pricing 248

pharmaphorum

JANUARY 15, 2021

With the new goals, GSK aims to have a net zero impact on climate and a net positive impact on nature by 2030. He highlights GSK’s recently announced sustainability ambitions as an example of how the company is aiming to “do the right thing” for wider society.

Drug Development 105

Drug Development Vaccines 105

Safe Biologics

JUNE 12, 2023

Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. More information will be available soon. Mr. Spiegel is a founding member of ASBM and Executive Director of the Global Colon Cancer Association.

Biosimilars 130

Biosimilars Drug Pricing Compounding Drug Development 130

European Pharmaceutical Review

MAY 11, 2023

By 2030, 20-25 gene therapies are expected to reach market approval, accounting for 1.30-1.61 As such, we acknowledge the cruciality of newborn screening (NBS) for SMA, advocating for its implementation globally. What are the emerging modalities in the gene therapy sector? percent of Europe’s annual healthcare spend.

Drug Development 95

Drug Development 95